Novel glutamine antagonists and uses thereof

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F22%3A00580592" target="_blank" >RIV/61388963:_____/22:00580592 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/patent/search/family/065994832/publication/EP3692015B1?q=EP3692015B1" target="_blank" >https://worldwide.espacenet.com/patent/search/family/065994832/publication/EP3692015B1?q=EP3692015B1</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Novel glutamine antagonists and uses thereof
Original language description
Glutamine antagonists and their use for treating oncological, immunological, and neurological diseases are disclosed. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof. Also disclosed are methods of enhancing the effects of an immune checkpoint inhibitor, enabling a subject to respond to an immune checkpoint inhibitor, or enabling the toxicity or the dose or number of treatments with an immune checkpoint inhibitor to be reduced, comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof, and an immune checkpoint inhibitor. Also disclosed are methods for treating an oncological, immunological, infectious or neurological disease or disorder that is refractory to checkpoint inhibitor therapy, the method comprising administering to a subject in need thereof, and having the refractory disease or disorder, a therapeutically effective amount of a glutamine antagonist of the disclosure or the pharmaceutical composition thereof.
Czech name
—
Czech description
—

Project
<a href="/en/project/LTAUSA18166" target="_blank" >LTAUSA18166: Tumor targeted prodrugs of glutamine antagonists</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
EP3692015
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Aug 24, 2022
Owner name
The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)